Gene therapies for lysosomal disorders

A gene and vector technology, applied in the field of gene therapy for lysosomal disorders, can solve problems such as difficult treatment of Gaucher's disease

Pending Publication Date: 2021-03-12
ПРЕВЕЙЛ ТЕРАПЬЮТИКС ИНК
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, other aspects of Gaucher's disease (particularly those affecting the bones and brain) appear to be difficult to treat

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Gene therapies for lysosomal disorders
  • Gene therapies for lysosomal disorders
  • Gene therapies for lysosomal disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0134] Example 1: rAAV vector

[0135] AAV vectors are produced using cells such as HEK293 cells for triple plasmid transfection. ITR sequences flank expression constructs containing promoter / enhancer elements, 3' polyA signals, and post-translational signals such as WPRE elements for each transgene of interest. Multiple gene products such as GBA1 and LIMP2 and / or prosaposin can be expressed simultaneously by fusion of protein sequences, or using 2 peptides with added amino acids due to prevention of peptide bond formation 2A peptide linkers of fragments such as T2A or P2A are achieved either using an IRES element or by expression with 2 separate expression cassettes. The presence of highly spliced ​​short intronic sequences upstream of the expressed gene can increase expression levels. shRNA and other regulatory RNAs can potentially be included in these sequences. Examples of expression constructs described in this disclosure are shown in Figure 1-8 and 21-35 and in Tabl...

Embodiment 2

[0139] Example 2: Cell-Based Assay for Viral Transduction in GBA Deficient Cells

[0140] GBA1-deficient cells are obtained as eg fibroblasts, monocytes or hES cells from GD patients or patient-derived induced pluripotent stem cells (iPSCs). These cells accumulate substrates such as glucosylceramide and glucosphingosine (GlcCer and GlcSph). Treatment of wild-type or mutant cultured cell lines with Gcase inhibitors, such as CBE, has also been used to obtain GBA-deficient cells.

[0141] Using these cell models, lysosomal defects are quantified by accumulation of protein aggregates such as α-synuclein aggregates, using antibodies against this protein or phosphorylated αSyn, and then by imaging using fluorescence microscopy. Lysosomal abnormalities have also been imaged by ICC against protein markers such as LAMP1, LAMP2, LIMP1, LIMP2 or using dyes such as Lysotracker, or by uptake of fluorescent dextran or other markers through endocytic compartments. Accumulation of autophagy...

Embodiment 3

[0143] Example 3: In vivo assay using mutant mice

[0144] This example describes an in vivo assay of AAV vectors using mutant mice. In vivo studies of AAV vectors in mutant mice as described above, using, for example, Liou et al. (2006) J. Biol. Chem. 281(7):4242-4253, Sun et al. 46:2102–2113 and the assay described by Farfel-Becker et al., (2011) Dis. Model Mech.4(6):746–752.

[0145] Medium control and AAV vector (for example, in 2×10 11 Intrathecal or intracerebroventricular delivery of vg / mouse) is performed using concentrated AAV stocks, for example, with injection volumes between 5-10 μL. Intraparenchymal delivery is by convective enhanced delivery.

[0146] Treatment begins before or after symptoms appear. Endpoints measured were substrate accumulation in the CNS and CSF, accumulation of Gcase enzymes as determined by ELISA and enzymatic activity, motor and cognitive endpoints, lysosomal dysfunction, and α-synuclein monomers, fibrils Accumulation of filaments or f...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to gene therapies for lysosomal disorders. In particular, the present disclosure relates, in certain aspects, to compositions and methods for treating diseases associatedwith abnormal lysosomal function, such as Parkinson's disease (PD) and Gaucher's disease. In certain embodiments, the present disclosure provides expression constructs comprising a transfection geneencoding beta glucocerebrosidase (GBA), or a portion thereof, alone or in combination with one or more PD-associated genes. In certain embodiments, the present disclosure provides methods of treatingParkinson's disease by administering these expression constructs to a subject in need thereof.

Description

[0001] The application date is October 3, 2018, the international application number PCT / US2018 / 054227 entered the Chinese national phase on May 22, 2020, the application number is 201880075846.8, and the title of the invention is "gene therapy for lysosomal disorders" divisional application of the application. [0002] related application [0003] This application claims U.S. Provisional Application Serial No. 62 / 567,296, filed October 3, 2017, entitled "GENETHERAPIES FOR LYSOSOMAL DISORDERS," 62 / 567,311 of "GENE THERAPIES FOR LYSOSOMALDISORDERS," filed October 3, 2017, "GENETHERAPIES FOR LYSOSOMAL DISORDERS" 62 / 567,319, 62 / 567,319, filed October 3, 2017, entitled "GENE THERAPIES FOR LYSOSOMAL DISORDERS," and 62 / 567,301, filed October 3, 2017, entitled "For 62 / 567,310 of GENE THERAPIES FOR LYSOSOMALDISORDERS for the benefit of 35 U.S.C. 119(e), the entire contents of each application are incorporated herein by reference. Background technique [0004] Gaucher's disease is a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/12C12N15/864C12N7/01C12N15/866C12N5/10A61K38/17A61K48/00A61P25/28A61P25/16
CPCC12N15/86A61K48/0075A61P25/28C12N2750/14143C07K14/47C12N7/00A61P25/16C12N2800/22C12N2750/14121C12N2710/14043A61K38/00C12Y302/01045C12N9/2402A61K48/005A01K2207/20A01K2217/075A01K2227/105A01K2267/0306C12N2750/14122A61K9/0019A61K9/0085A61K35/76A61K39/23A61K48/0058C07H21/04C07K14/005C07K14/435C07K14/61C07K14/70503C12N15/8645C12N2750/14022C12N2750/14043A61K48/00C07K14/475A61K35/761C12N2830/50C12N2830/48
Inventor 阿萨·阿贝利奥维奇劳拉·赫克曼赫维·莱茵
Owner ПРЕВЕЙЛ ТЕРАПЬЮТИКС ИНК
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap